Overview
2005Founded1
Compare with GT Biopharma, Inc., Rafael Holdings, Inc. or IMPACT BIOMEDICAL INC., or pick any stock.
- TickerTLPH on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersRedwood City1
- Websitewww.acelrx.com
- Incorporated inDE4
- Business address1850 Gateway Drive, Suite 175, San Mateo, Ca 944044
- Filer categoryNon-accelerated filer, Smaller reporting company4
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development45¢$6.0M
- Selling, general and admin55¢$7.5M
Out of $28.0K in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $28.0K | $0 |
| Research and development | $6.0M | $6.7M |
| Selling, general and administrative | $7.5M | $8.5M |
| Total operating costs and expenses | $13.5M | $15.3M |
| Loss from operations | -$13.5M | -$15.3M |
| Interest income and other income, net | $436.0K | $679.0K |
| Gain on sale of future payments | $0 | $1.2M |
| (Loss) gain on change in fair value of warrant liability | -$1.3M | $717.0K |
| Non-cash interest expense on liability related to the sale of future payments | $0 | -$394.0K |
| Total other income, net | -$879.0K | $2.2M |
| Net loss from continuing operations | -$14.4M | -$13.0M |
| Net income from discontinued operations See Note 3 | $73.0K | $0 |
| Net loss | -$14.3M | -$13.0M |
| Basic and diluted, continuing operations (in dollars per share) | -$0 | -$0 |
| Basic and diluted, discontinued operations (in dollars per share) | $0 | $0 |
| Basic and diluted loss per share (in dollars per share) | -$0.34 | -$0.50 |
| Shares used in computing net loss per share of common stock, basic and diluted See Note 10 (in shares) | 42.4M shares | 25.8M shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2025-08-31 | 2025-03-31 |
|---|---|---|---|
| Cash and cash equivalents | $5.9M | ||
| Short-term investments | $14.5M | ||
| Prepaid expenses and other current assets | $519.0K | ||
| Total current assets | $20.9M | ||
| In-process research and development asset | $8.8M | ||
| Total assets | $29.7M | ||
| Accounts payable | $544.0K | ||
| Accrued and other liabilities | $2.6M | ||
| Liabilities of discontinued operations, current portion | $650.0K | ||
| Total current liabilities | $3.8M | ||
| Warrant liability | $2.4M | ||
| Liability related to the sale of future payments | $6.5M | ||
| Total liabilities | $12.7M | ||
| Common stock, $0.001 par value200,000,000 shares authorized as of December 31, 2025 and 2024; 49,328,097 and 17,029,469 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $49.0K | ||
| Additional paid-in capital | $488.5M | ||
| Accumulated deficit | -$471.5M | ||
| Total stockholders equity | $17.0M | ||
| Total Liabilities and Stockholders Equity | $29.7M | ||
| Common Stock, Par or Stated Value Per Share (in dollars per share) | $0.00 | $0.00 | $0.00 |
| Common Stock, Shares Authorized (in shares) | 200.0M shares | ||
| Common Stock, Shares, Issued (in shares) | 49.3M shares | ||
| Common Stock, Shares, Outstanding (in shares) | 49.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$14.3M | -$13.0M |
| Non-cash revenue related to sale of future payments | -$28.0K | $0 |
| Non-cash interest expense on liability related to sale of future payments | $0 | $394.0K |
| Net amortization of discount on short term investments | -$142.0K | -$121.0K |
| Stock-based compensation | $699.0K | $989.0K |
| Revaluation of warrant liability | $1.3M | -$717.0K |
| Prepaid expenses and other current assets | $35.0K | $1.6M |
| Accounts payable | -$208.0K | -$671.0K |
| Accrued liabilities | $1.3M | -$1.2M |
| Net cash used in operating activities | -$11.4M | -$12.7M |
| Purchase of investments | -$17.8M | -$5.0M |
| Proceeds from sale of investments | $10.0K | $0 |
| Proceeds from maturities of investments | $3.5M | $8.8M |
| Net cash (used in) provided by investing activities | -$14.3M | $3.8M |
| Gross proceeds from sale of future payments | $0 | $6.7M |
| Issuance costs related to sale of future payments | $0 | -$521.0K |
| Net proceeds from issuance of common stock through equity plans | $17.0K | $27.0K |
| Net cash provided by financing activities | $22.7M | $12.0M |
| Net change in cash and cash equivalents | -$3.0M | $3.1M |
| Equity issuance costs from warrant modification | $0 | $251.0K |
| Offering costs in accounts payable and accrued liabilities | $116.0K | $0 |
Compare AcelRx Pharmaceuticals (United States) with another company
Former names
- ACELRX PHARMACEUTICALS INCFeb 19, 2008 to Dec 14, 20234
Timeline
- 2005Founded Founded1
Recent filings
- Aug 12, 2026SCHEDULE 13G/A
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Aug 12, 2026S-8
- Jun 24, 20264
- Jun 24, 20264
- Jun 24, 20264
- Jun 24, 20264
- Jun 24, 20264
- Jun 24, 20264
- Jun 24, 20264
- Jun 23, 20268-K
- May 21, 20264
- May 15, 2026SCHEDULE 13G/A
- May 13, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.acelrx.com1
- WikidataQ30270758
- SEC EDGARCIK 1427925
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websiteAcelRx Pharmaceuticals (United States) logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12